News for Supernus Pharmaceuticals, Inc. (0LB2.L)

Total Revenue: $149.8 million in Q1 2025, up from $143.6 million in Q1 2024.Net Product Sales: $142 million in Q1 2025.Royalty Revenues: $7.8 million in Q1 202

May 06, 2025 / 08:30PM GMTOperator Good afternoon and welcome to Supernus Pharmaceuticals first-quarter 2025 financial results conference call. (Operator Instru

First quarter 2025 net sales of Qelbree® increased 44% to $64.7 million, compared to the same period in 2024.First quarter 2025 net sales of GOCOVRI® increase

Supernus Pharmaceuticals (SUPN) announced first quarter revenue reaching $149.8 million, surpassing the anticipated $147.94 million. This achievement underscore

Total Revenue: $149.8 million, surpassing the estimated $146.94 million, marking a 4% increase year-over-year.Earnings Per Share (EPS): Reported a loss of $(0.

On March 31, 2025, BlackRock, Inc. (Trades, Portfolio) executed a significant transaction involving Supernus Pharmaceuticals Inc (SUPN). The firm reduced its ho

Supernus Pharmaceuticals (SUPN) is set to release its first quarter 2025 financial results on May 6, 2025, after market close. The company will host a c

**media[603737]**

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc.

We recently compiled a list of the 10 Cash-Rich Small Cap Stocks To Invest In According To Analysts. In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc.

Small-cap stocks in the US have been under pressure, with the Russell small cap index falling 10% from its November highs as of January 2025.

Supernus Pharmaceuticals Inc (SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, announced on March 4, 2025, that its Pre

ROCKVILLE, Md., March 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. ( SUPN), a biopharmaceutical company focused on developing and commercializi

We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now. In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals Inc (SUPN) showcases a robust portfolio in CNS treatments, with a recent FDA approval expanding its market reach.Despite strong produc

Supernus Pharmaceuticals Inc (SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, announced on February 27, 2025, that its

ROCKVILLE, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. ( SUPN), a biopharmaceutical company focused on developing and commercializin

Total Revenue (Q4 2024): $174.2 million, up from $164.3 million in Q4 2023.Net Product Sales (Q4 2024): $166.4 million.Operating Earnings (Q4 2024, GAAP): $21.

Feb 25, 2025 / 09:30PM GMTOperator Good afternoon and welcome to Supernus Pharmaceuticals fourth quarter and full-year 2024 financial results conference call. (